Emerging effects of sevelamer in chronic kidney disease

Kidney and Blood Pressure Research

Volumn 37, Issue 1, 2013, Pages 24-32

  Ikee, Ryota ^a   Tsunoda, Masataka ^a   Sasaki, Naomi ^a   Sato, Naritsugu ^a   Hashimoto, Nobuo ^a  

^a H N Medic Kitahiroshima ^*  (Japan)

Author keywords

Cardiovascular disease; CKD MBD; Phosphate binder; Sevelamer

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIANEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; CALCIUM ACETATE; CALCIUM CONTAINING PHOSPHATE BINDING AGENT; CD14 ANTIGEN; FETUIN A; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 10; INTERLEUKIN 6; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; REACTIVE OXYGEN METABOLITE; SEVELAMER; SEVELAMER CARBONATE; TRACE ELEMENT; UNCLASSIFIED DRUG;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; BICARBONATE BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DENSITY; BONE STRUCTURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COPPER BLOOD LEVEL; DISEASE COURSE; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; OSSIFICATION; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SIDE EFFECT; ZINC BLOOD LEVEL; CARDIOVASCULAR MORTALITY; DISEASE CONTROL; DRUG METABOLISM; DRUG POTENCY;

ANIMALS; CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84874802842     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000343397     Document Type: Review

References (54)

1. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int 2010;78:S10-S21.
2. Patel T, Singh AK: Role of vitamin D in chronic kidney disease. Semin Nephrol 2009;29:113-121.
3. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
4. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
5. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
6. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J: Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-1661.
7. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
8. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and antiinflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-825.
9. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A: Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011;57:422-431.
10. Raggi P, Bommer J, Chertow GM: Valvular calcification in hemodialysis patients randomized to calciumbased phosphorus binders or sevelamer. J Heart Valve Dis 2004;13:134-141.
11. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012;59:177-185.
12. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61-68.
13. Boaz M, Katzir Z, Schwartz D, Gafter U, Biro A, Shtendik L, Kon V, Chernin G, Weinstein T: Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. Nephrol Clin Pract 2011;117:c83-c88.
14. Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, Shikuma S, Ishigami J, Tajima M, Asai T, Okado T, Kuwahara M, Sasaki S, Tsukamoto Y: Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 2012;16:930-937.
15. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008;110:c273-c283.
16. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M, CARE-2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-965.
17. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
18. Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE: Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32:617-624.
19. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137.
20. St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-454.
21. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators: Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487-493.
22. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-772.
23. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-412.
24. Negishi K, Kobayashi M, Ochiai I, Yamazaki Y, Hasegawa H, Yamashita T, Shimizu T, Kasama S, Kurabayashi M: Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ J 2010;74:2734-2740.
25. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
26. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
27. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy. Clin J Am Soc Nephrol 2010;5:286-291.
28. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M: Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25:2672-2679.
29. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J: Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2272-2279.
30. Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho JT, Batista MC, Cuppari L, Carvalho AB, Moyses RM, Guimaraes N, Jorgetti V, Andreoli MC, Draibe SA, Cendoroglo M: Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodial Int 2009;13:271-277.
31. Sun PP, Perianayagam MC, Jaber BL: Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr 2009;19:432-438.
32. Del Vecchio L, Locatelli F, Carini M: What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention. Semin Dial 2011;24:56-64.
33. Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY, Tsai TJ, Wu KD, Wu MS: Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig 2011;31:257-267.
34. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012;7:934-942.
35. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW; Netherlands cooperative study on the adequacy of Dialysis (NECOSAD): Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007;72:202-207.
36. Portoles J, Lopez-Gomez JM, Aljama PA: A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant 2007;22:500-507.
37. Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S, Asano Y, Hasegawa T, Port FK, Kurokawa K: Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 2008;23:3643-3653.
38. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N: Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients. Nephrology (Carlton) 2012;17:225-229.
39. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C, RISCAVID Study Group: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011;26:2641-2648.
40. Weiss G, Gooodnough LT: Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
41. Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M: Uremic toxins and oral adsorbents. Ther Apher Dial 2011;15:132-134.
42. Schiffl H, Lang SM: Phosphate binder is not phosphate binder! Sevelamer may be different! Nephrol Dial Transplant 2011;26:377-378.
43. Takagi K, Masuda K, Yamazaki M, Kiyohara C, Itoh S, Wasaki M, Inoue H: Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 2010;73:30-35.
44. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N: Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients. Int Urol Nephrol DOI: 10.1007/s11255-012-0211-3.
45. Veighey K, Booth J, Davenport A: Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis. Nephrol Dial Transplant 2011;26:1006-1010.
46. Koca T, Berber A, Koca HB, Demir TA, Koken T: Effects of hemodialysis period on levels of blood trace elements and oxidative stress. Clin Exp Nephrol 2010;14:463-468.
47. Ari E, Kaya Y, Demir H, Asicioglu E, Keskin S: The correlation of serum trace elements and heavy metals with carotid artery atherosclerosis in maintenance hemodialysis patients. Biol Trace Elem Res 2011;144:351-359.
48. Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, Shigematsu T, ROD 21 Clinical Research Group: Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-346.
49. Kasai S, Sato K, Murata Y, Kinoshita Y: Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Ther Apher Dial 2012;16:341-349.
50. Sonikian M, Gogusev J, Zingraff J, Loric S, Quednau B, Bessou G, Siffert W, Drueke TB, Reusch HP, Luft FC: Potential effect of metabolic acidosis on beta 2-microglobulin generation: in vivo and in vitro studies. J Am Soc Nephrol 1996;7:350-356.
51. Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N: A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2009;24:3794-3799.
52. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009;72:252-258.
53. Chan WL, Rounsley K, Chapman E, Collings K, Dale C, De Waal S, Patel V, Tanner J, Turner E, Moore J, Borrows R: Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. J Ren Nutr 2010;20:270-277.
54. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drueke TB, Massy ZA: Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012;27:505-513.